Genprex (NASDAQ:GNPX) Stock Price Down 2.8% – Here’s Why

Genprex (NASDAQ:GNPX)’s stock price traded down 2.8% during trading on Monday . The stock traded as low as $0.8306 and last traded at $0.8453. 378,736 shares were traded during mid-day trading, a decline of 71% from the average session volume of 1,289,422 shares. The stock had previously closed at $0.87.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Genprex in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Genprex presently has a consensus rating of “Sell”.

Genprex Trading Down 2.8%

The business’s fifty day moving average price is $1.52 and its two-hundred day moving average price is $2.60. The firm has a market cap of $8.81 million, a P/E ratio of -0.03 and a beta of -0.94.

Institutional Trading of Genprex

Institutional investors and hedge funds have recently made changes to their positions in the stock. Mayflower Financial Advisors LLC acquired a new position in shares of Genprex during the 1st quarter valued at about $36,000. Manchester Financial Inc. acquired a new stake in Genprex in the 1st quarter worth approximately $36,000. Finally, Susquehanna International Group LLP lifted its holdings in Genprex by 11.7% in the 3rd quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock worth $58,000 after purchasing an additional 35,661 shares during the last quarter. Institutional investors and hedge funds own 14.05% of the company’s stock.

About Genprex

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.